For the year ending 2025-12-31, VYGR has $252,281K in assets. $56,200K in debts. $65,300K in cash and cash equivalents.
| Balance Sheets | 2025-12-31 | |||
|---|---|---|---|---|
| Cash and cash equivalents | 65,300 | |||
| Marketable securities | 131,147 | |||
| Accounts receivable | 1,761 | |||
| Related party collaboration receivable | 151 | |||
| Prepaid expenses and other current assets | 4,328 | |||
| Total current assets | 202,687 | |||
| Property and equipment, net | 13,136 | |||
| Restricted cash | 2,736 | |||
| Marketable securities | 5,244 | |||
| Operating lease right-of-use assets | 28,478 | |||
| Total assets | 252,281 | |||
| Accounts payable | 5,013 | |||
| Accrued expenses | 12,098 | |||
| Operating lease liabilities | 7,840 | |||
| Deferred revenue | 1,590 | |||
| Total current liabilities | 26,541 | |||
| Operating lease liabilities, net of current portion | 28,659 | |||
| Other non-current liabilities | 1,000 | |||
| Total liabilities | 56,200 | |||
| Common stock, 0.001 par value 120,000,000 shares authorized 59,047,860 and 54,731,316 shares issued and outstanding at december 31, 2025 and 2024, respectively | 59 | |||
| Additional paid-in capital | 641,895 | |||
| Accumulated other comprehensive income (loss) | 32 | |||
| Accumulated deficit | -445,905 | |||
| Total stockholders' equity | 196,081 | |||
| Total liabilities and stockholders' equity | 252,281 | |||
Voyager Therapeutics, Inc. (VYGR)
Voyager Therapeutics, Inc. (VYGR)